ISBER 2021 Preliminary Program

Qualification in Biorepository Science

Success is the Result of Preparation: Emergency Planning for Biobanking

Presented by:

• Helen Morrin, University of Otago Christchurch, New Zealand
• Rebecca Pugh, National Institute of Standards and Technology, USA

Emergencies can occur everywhere and Biobanks are just as likely as every other industry to suffer the consequences of poor planning. This session will help you build a culture of preparedness to ensure that your assets (specimens, data, infrastructure and staff) can be protected from disasters, such as the recent COVID-19 pandemic. Interactive discussions and activities will address risk assessment, crisis management, critical response procedures, planning for natural disasters, as well as data protection and recovery. This workshop will offer the opportunity to discuss the unique emergencies that may affect your operations and offer solutions to help you create your own emergency plans.

Learning Objectives:

• Understand the importance and role of emergency and disaster planning in biobank management and sustainability
• Understand the components and tools for creating one's own emergency and disaster response plans
• Understand the stages of preparedness, response and recovery throughout an emergency

Basic Business Planning for Biobanking

Presented by:

• Marianne Henderson, National Cancer Institute, USA
• Daniel Simeon-Dubach, medservice, Switzerland
• Kirstin Goldring, AstraZeneca, UK

Successful Biobanking operations begin with accurate and responsible planning. This session will provide guidance on how fulfill your banks mission by formulating a business plan that will satisfy stakeholders through the use of SMART performance metrics and audit points. Discussions will include infrastructure assessments, Funding and cost management as well as SWOT analysis.

Learning Objectives:

• The importance and role of business planning in biobank management and sustainability
• The basic components of a business plan
• How Vision and Mission statements keep biobanks focused
• How to identify and manage internal and external factors affecting biobank operations and performance
• Metrics used in tracking biobank activity, progress and success

Welcome to the ISBER 2021 Annual Meeting
Daniel Catchpoole, ISBER President 2020-2021

Daily Briefing
Amanda Moors and Benjamin Otto, ISBER 2021 Program Committee Co-Chairs

Keynote Lecture
Speaker TBD

Lesson to be Learned from the COVID-19 Pandemic

Collaboration and sharing of expertise, of samples and of data across academia, industry and governmental institutions is vital for medical research, for successful development of diagnostics tests and treatments but as well for sustainability of research projects. The Covid-19 pandemic, in a microcosmic way, has made the value of successful collaboration between medical centers, academia and Pharma / Biotec clearly visible. Never before have diagnostic tests and effective vaccines been developed in such a short time. This success story however should not end with the recession of the Covid-19 pandemic – rather it should be a rallying cry for more future collaboration. Within this session we would like to reflect on the year 2020, on lessons learned, obstacles and opportunities to foster closer cooperations across the aisle.

The Pathway of a Sample from Acquisition to Value Creation
Vanessa Tumilasci, Trans-Hit Biomarkers, a Brooks Life Sciences Company, Canada

Lessons to Learn from the Corona Pandemic - Intense Data- and Sample Transfer as Key Success Factor for Rapid Development of Diagnostic Tools
Andreas Pfützner, Pfützner Science & Health Institute, Germany

Human Antibodies for SARS-CoV-2
James Crowe, Vanderbilt University Medical Center, USA

Title TBD
Beatus Ofenloch-Haehnle, Roche Diagnostics, Germany
Chitra Manohar, Roche Diagnostics, USA

Title TBD
Nikolaos Gaitatzis, Nexelis GSK, Germany

The Microbiome - Making a Macro-Impact

Publications for microbiome research have been increasing exponentially. Research shows microbiota impact human, animal, plant, and environmental health significantly. By integrating sequencing and metabolomics, researchers are looking for relationships between microbiomes, health, and disease. The aim of this session is to showcase the possibilities and limitations associated with microbiome research.

Ecological Perspectives on Skin Microbiomes
Woo Jun Sul, Chung-Ang University, South Korea

Microbiomes from Biorepositories
Stephen Greiman, Georgia Southern University, USA

Collecting and Banking Biospecimens for Microbiome Research in Large Cohort Studies
Wei Zheng, Vanderbilt University Medical Center, USA

SARS-CoV-2 Detection Status Associates with Bacterial Community Composition in Patients and the Hospital Environment
Lisa Marotz, University of California, San Diego, USA

Liquid Biopsy in Cancer Patients

Biobanking, pre-analytical and analytical steps are important steps to detect circulating biomarkers in blood samples from patients with a solid cancer. Liquid biopsy-based assays will be introduced in clinical routine in the near future. However, we need to initiate more intervention clinical trials, combine different circulating biomarkers depending on the cancer type, and define guidelines and SOP for their analyses.

Biobanking of Liquid Biopsy in Lung Cancer: Opportunities and Issues
Paul Hofman, Université Côte d'Azur, France

Extracellular Vesibles: From Cell-Cell Communication to Biomarkers
Bruno Costa -Silva, Champalimaud Foundation, Portugal

Utility of Circulating Tumor DNA as a Response and Follow-Up Marker in Cancer Therapy
Ellen Heitzer, Medical University of Graz, Austria

Non-Coding Patterns and Liquid Biopsy
George Calin, MD Anderson Cancer Center, USA

Assessing and Addressing the Ethical and Governance Challenges of Networking Biorepositories

Presented by:

• Aaron Goldenberg, Case Western Reserve University, USA
• Kyle Brothers, University of Louisville, USA
• Jean Cadigan, University of North Carolina, USA

This workshop will explore the unique ethical and governance questions raised by networked biorepositories. We will first discuss data from a mixed-methods study of the perspectives and experiences of stakeholders actively engaged in designing, operating, and governing networked biorepositories. The overall aim of this project is to characterize the ethical and regulatory challenges created by existing and proposed models for networked biorepositories, and identify policy and practice solutions available for addressing these challenges.

We will then split participants into small groups and provide each group with a different case study based on a challenges encountered by networks in our study. Participants will have an opportunity to review and discuss their assigned case, with the goal of identifying and prioritizing possible solutions.

Finally, we will utilize the feedback from the workshop and our presented data to collaboratively identify possible best practices for governance and oversight structures best suited for addressing the unique challenges and opportunities in networked biorepositories.

Practical Applications of Digital Pathology and Artificial Intelligence in Biobanking

Presented by: Anil Parwani, The Ohio State University, USA

This workshop will provide an overview of digital pathology and AI tools currently being used in the pathology workflow and to provide practical insights into the use of these technologies into transforming the workflow of a modern biobank. A framework of knowledge will be provided by an extended and interactive Q&A session which will serve to demystify the use of WSI, artificial intelligence and image analysis tools for biobanking applications, implementation challenges and pearls.

Keeping Biobanking Simple: If kids get it, so will you

Presented by:

• Mandy Riffel, Children's Mercy Hospital, USA
• Daniel Catchpoole, The Children's Hospital at Westmead, Australia
• Suzanne Vercauteren, BC Children's Hospital Biobank, Canada

During this workshop, participants will be given tools to develop a marketing plan for their individual biobanks that not only uses plain language but also utilizes creative language to engage biobank participants. Participants will hear two successful marketing plans from Pediatric Biobanks. Participants will have the opportunity to practice the usage of these tools by working in small groups to create a plain language, engaging marketing campaign for The Biobank of Imaginary Friends located at the North Pole with feedback from presenters.

Coffee and Networking

Join us for networking with fellow delegates from around the globe.

Top of the Morning

Join us as the ISBER 2021 Program Committee co-chairs review the meeting so far and discuss what to expect on day 2.

Research and Treatment for All – Connecting Research and Implementation to Underserved and Vulnerable Communities

Biorepository specimens and data can only fulfill their potential to truly transform health and accelerate scientific discovery if the outcomes are robust and meaningful for all. Biobanks need to be inclusive of all populations, including the underserved and vulnerable communities to address the current lack of diversity and genetic bias, in addition to reducing health disparities. The advent of precision medicine and increased use of genomic tools (including WGS, WES, targeted gene panels, somatic sequencing in cancer, etc.) in both clinical medicine and research has highlighted the urgency to acquire samples from diverse genetic populations and ancestral communities to create meaningful results for all groups. Engagement with these communities face additional challenges, requiring sensitive responses to building trust and partnerships, to meet each community's needs. This session will include a discussion of the stigma of COVID-19 positivity/disease in these communities.

How To Fail at Connecting with Vulnerable and Underserved Populations to Implement Treatment and Research
Paula Kim, TRAC-Translating Research Across Communities, USA

Nexus between Science and Society: Southern African Experience
Himladevi Soodyall, Academy of Science of South Africa (ASSAf), South Africa

Recruiting Black and Brown Women to the Komen Tissue Bank: A Motivational Roadmap
Kathi Ridley-Merriweather, Susan G. Komen Tissue Bank at the IU Simon Cancer Center, USA

The Nurture of Nature: Environmental Biobanking for a Connected World

The vastly diverse environmental collections serve as an invaluable resource of knowledge--while this diversity is necessary for the understanding of biodiversity, as well as other topics, it also introduces challenges to maintaining a connectedness in a field that has historically been defined by what it is not (i.e., human). Since plants, animals, archaea, and other environmental collections/samples do not possess a human voice, there is a risk that they will not be heard. Without the knowledge provided and preserved through environmental biobanking, though, there is an even greater risk to the prosperity of humanity. This Symposium will provide a platform for environmental biobanks to tell their stories about the diverse collections and the value they provide for the biobanking community and beyond.

Integrating the North Pacific through Two Decades of Banking Seabird Eggs
Stacy Schuur, National Institute of Standards and Technology, USA

The Nature of Nurturers and Nurturers in Nature; The story of the Collaborative Bristol Bay Beluga Project
Eric Gaglione, Georgia Aquarium, USA
Carrie Goertz, Alaska Sea Life Center, USA

Implementing a Quality Management System in CGIAR Genebanks: Improving the Alignment of People, Policy and Technology in the World’s Largest and Most Diverse Collections
Janny van Beem, Crop Trust, USA

Brazilian Genetic Resources Biobanks Network
Samuel Paiva, Embrapa Embrapa Genetic Resources and Biotechnology, Brazil

Oral Abstract Presentations

Effect of Ascorbic Acid on Metabolic Status, Lipid Peroxidation, Antioxidant Activity and Quality of Frozen Indian Red Jungle Fowl (Gallus gallus murghi) Semen
Bushra Allah Rakha, Pir Mehr Ali Shah Arid Agriculture University Rawalpindi, Pakistan

Hla Typing From Dried Blood Spots Using Lifecodes Sso Typing Kit
Maemu Gededzha, University of the Witwatersrand Faculty of Health Sciences, South Africa

Biobanking in the Era of COVID-19: Ethical and Governance Challenges
Aaron Goldenberg, Case Western Reserve University, USA

COVID-19 Biorepository - Qatar
Eleni Fthenou, Qatar Biobank for Medical Research, Qatar

Oral Abstract Presentations

Coordinating COVID-19 Tissue Procurement from Autopsy: Challenges and Lessons Learned
Aubrey Schild, Duke University, USA

Establishment, Implementation and Utilization of a Human COVID-19 Biospecimen Biorepository at UCLA
Clara Magyar, University of California Los Angeles David Geffen School of Medicine, USA

A Paradigm Shift - Re-purposing Resources and Infrastructure During a Pandemic to Ensure Sustainability
Sangita Paul, University Health Network, Canada

QCBio-AF: Qatar Cardiovascular Biorepository for Familial Atrial Fibrillation
Fatima Mohammed Qafoud, Qatar Foundation Research and Development, Qatar University,Qatar

Transitioning to an Automated Biobank: Advantages, Best Practices and Case Study

• Michelle Ng Almada, BiOS Product Manager, Hamilton Storage

Automated biobanking technologies offer advantages over traditional manual storage systems for protecting sample integrity and security, streamlining biobanking activities, and making the most efficient use of space and energy. During this workshop, we will first provide an overview of the beneficial role that automation plays in biobanking applications, then delve into how automated sample handling devices and automated storage systems support a high-throughput workflow. We will also offer general guidelines for setting up and achieving the highest efficiency with automated biobanking at any scale, from compact and localized to large modular solutions.

Finally, we will provide a case study on the National Centralized Repository for Alzheimer’s and Related Dementias (NCRAD) at the Indiana University School of Medicine, Indianapolis, IN, USA. NCRAD is consolidating multiple collections of manually stored samples totaling over 3.5 million (including DNA, cerebrospinal fluid, brain tissue, and more) into a single automated storage system. Automated storage processes will enable NCRAD’s biorepository operations team to cut sample turnaround in half and remove sources of variability in sample storage, thus ensuring that all research supported by the facility is robust and reproducible.

Hosted by:

Title TBD

The details for this session will be available shortly.

Hosted by:

Poster Abstract Presentations

Join us in the poster hall to peruse the latest research in biobanking and connect directly with the poster presenters. All poster presenters are available within their poster booth to videoconference with delegates.

Networking with China and the Indo-Pacific Rim

Join us for networking with fellow delegates from around the globe.

Round Table Discussions

Biobanking in LMICs in the Post COVID-19 Era
Facilitator: Zisis Kozlakidis, International Agency for Research on Cancer, France

Aaaah! I'm being audited! - Project Management Tools for a Successful Audit
Facilitator: Matthew Eby, Booz Allen Hamilton, USA

Integrating New Collections into Well Established, Highly Diverse Central Repositories
Facilitator: Kurt Langenbach, Precision for Medicine, USA

Impact of New Diagnostic NMR-Tools on Biobank Sample Quality and Efficiency
Facilitator: Roland Leiminger, Bruker BioSpin GmbH, Germany

The Future Role of Biobanking in the Coming Cell and Gene Therapeutics Revolution
Facilitator: Jennifer Shrider, Stirling Ultracold, USA

Compliance Experience in Pharma Useful for Academic Biobanks?
Facilitator: Erik Steinfelder, Thermo Fisher Scientific, USA

Challenges and Tips for Writing a Plain Language Consent Form
Facilitator: Helena Ellis, Biobanking Without Borders, LLC, USA

Top of the Morning

Join us as the ISBER 2021 Program Committee co-chairs review the meeting so far and discuss what to expect on day 3.

Biobanking in the Food Industry: Where Standards Are Easy to Digest!

Many food industries have systematic stores of biological materials used in food production that has to be maintained through to extremely high standards. Several international organizations of government currently cover biobanking for agriculture and food production. There are however gaps between governments and commercial industry regarding the food production business sector and the role of biobanking in these industries needs to be highlighted. This could involve an agribusiness stream in the discussion as well.

Lessons Learned from the NIST Food Reference Material Program
Melissa Meaney Phillips, National Institute of Standards and Technology, USA

Olive Genetic Resources Conservation and Cataloguing in the Germplasm Bank IOC Network: Gen4olive and THOC Projects
Pablo Morello, International Olive Council (IOC), Spain

Fermentation Microbes-The Real Workers in Innovative Products for the Future
Simon Dillon, Australian Wine Research Insitute, Australia

Standards and Quality in Your Kitchen
Jeanette Simeon-Dubach,Directnetwork GmbH, Switzerland

Biobank Sustainability in Light of the COVID-19 Pandemic

Sustainable behavior is a central focus for all research and clinical activities, including biobanking. The experience with the COVID-19 pandemic brought a new challenges in all aspects of our lives, let alone our work. It also has brought challenges as well as opportunities to sustained research biobanking and clinical care/biobanking. The symposium will highlight biobanking from several perspectives, including biobanking to serve the clinic and creation of the vaccines, as well as research biobanking. The speakers will share their perspectives and lessons-learned from before, during and on emerging from the pandemic, on the value and practicality of sustained biobanking. A panel discussion with audience participation will follow the talks.

What did COVID tell us about the value of biobanks?
Phil Quinlan, University of Nottingham , UK

Sustainable COVID-19 Sample Collection in Challenging Times
Amir Gander, University College London, UK

Examining Business Continuity Challenges for Biobanking Services During the COVID-19 Pandemic
Rohit Gupta, TMRW Life Sciences , USA

Strengths and Weaknesses in the Time of COVID-19 - Reflections from Sweden
Karolin Bergenstrahle, Uppsala University, Uppsala Biobank, Biobank Sweden, Sweden

I see QMS from Both Sides Now: Discovering the Net Benefit of Tools to your Biobank

Presented by:

• Clare Allocca, National Institute of Standards and Technology, USA
• Brent Schacter, CancerCare Manitoba/ University of Manitoba, Canada
• Emma Snapes, BioConsulting, Ireland

Biobank standards, best practices, and other tools and resources are critical for ensuring that biospecimens are fit for their intended purpose (FIP) and that the results of studies using biospecimens from biobanks are meaningful and reproducible. A key element for successful application of a number of these tools, and for achievement of FIP, is the presence of a Quality Management System (QMS). Following a review of the spectrum of FIP tools with specific emphasis on QMS, this workshop will explore considerations and potential benefits on “both sides” of the implementation of a QMS. A panel will pose and discuss several pre-QMS and post-QMS scenarios addressing the considerations process. Two parallel breakout sessions build on these discussions: 1) for those who have not yet implemented QMS, we will explore considerations and benefits, as well as tools that can assist with implementation; 2) for those who have already implemented QMS, we will explore options and considerations for next steps and address implications. Participants will explore and apply the principles discussed during the first half of the workshop to their own or a fellow participant’s scenario. Trends between groups will be identified and discussed during the summary session.

To Save (Share or Store) or Not to Save (Transfer or Destroy): A Value-Based Decision Tree Tool to Support Management of Collections in a Biobank

Presented by:

• Joseph Kessler, Medpace, USA
• Marianne Henderson, National Cancer Institute, USA
• Tali Johnson, National Cancer Institute, USA

As biospecimens across the world are sitting in freezers, monthly maintenance costs burden the guardians of the collections and their steward organizations. Are the samples in use today? Maybe they are new but must wait for time to use or share? Or are they legacy samples that may not be relevant today?

This workshop will present a new value-based decision-making tool – to support valuation (non-economic) and evaluation of collections in storage from across all biomedical sectors. The tool will allow biobankers or researchers a decision-making support to determine if each collection that they have in storage should be saved (investment in continued funding), shared (maybe kept or transferred to others or returned) or destroyed (no value, no ability to use due to lack of consent, etc.).

The workshop will focus on an overview of the tool and the decision-making interface involved in using it, how the decisions lead to a value score and how those scores could be used practically.

Informed Consent in Biobanking: From the Key Barriers, Challenges and Perceptions to the Digital Innovations

Presented by:

• Panagiotis Katsaounis, Metabio, Greece
• Desislava Ivanova, Metabio, Greece

The workshop’s goals and objectives introduce the importance of informed consent, an important part of the patients’ welfare system, including all the ethical, legal and practical implications. Starting with the concept of informed consent and its evolutionary course the past years and ending with the future perspectives, challenges and applications, the participants will be able to learn and investigate one of the most valuable tools in biobanking and clinical research. The workshop is consisted of detailed presentation of current consent types, statuses, aspects and processes, incorporating all the regulatory requirements and key elements, recommended for cybersecurity, ethics, privacy and data protection. Main barriers and perceptions will be also discussed, associated with the use of the consent in the current biobanking environment. Introduction to the real-time dynamic e-consent concept will be incorporated in the second part of the workshop presentation, addressing its application in the biobanking environment, the challenges of its integration, the benefits of patient’s active enrollment in their biosample value chain, the modifications adopted by the usage chain and the current biobank needs. Donation scenarios will be discussed, with participants acting as patient/donors or biobanks/researchers, creating real-life scenarios, discussing the different types of informed consent and come to a consensus, considering the interest, of both sides.

Round Table Discussions with China and the Indo-Pacific Rim

Research Priorities in Biobanking
Facilitator: Jennifer Byrne, The University of Sydney, Australia

Improving Trust in Biobanking
Facilitator: Birendra Kumar Yadav, National Liver Disease Biobank, Institute of Liver and Biliary Sciences, India

Coffee and Networking

Join us for networking with fellow delegates from around the globe.

Top of the Morning

Join us as the ISBER 2021 Program Committee co-chairs review the meeting so far and discuss what to expect on day 4.

Making Biospecimens an Informatics Challenge: Navigating Our Way to Innovation

Biospecimens are collected because they contain the information we require to understand biology, disease and the world we live in. Biobanks have become the "librarians" essential to unlocking the stories associated with each biospecimen. In vision the next generation of biobank having specimens enriched by clinical, molecular and Omics data, will biobanks need to be run as data-driven enterprises? Should they be active in the generation of vast amounts of computer readable information and its interrogation? How are biobanks preparing for a future where biospecimens are integral to an informatics driven discovery process, engaging with the informatics industries as active partners?

Beyond DNA: Extending EHR-Linked Biobanks to Protein Biomarker Discovery
Quinn Wells, Vanderbilt University Medical Center, USA

Challenges in Biomaterial Annotation and Data Integration
Michael Neumann, Interdisciplinary Bank of Biomaterials and Data Würzburg, Germany

Genomic Prediction and Inference from Population-Scale Datasets
Manuel Rivas, Stanford University, USA

ProCan: A Cancer Biospecimen Proteomic Data Collaboration
Roger Reddel, Children's Medical Research Institute, Australia

Data Sharing Network for Sharing Evidence-Based Solutions

In the global efforts to better understand coronavirus disease (COVID-19) biobanks continue to play a crucial role in providing tools to examine data from those receiving treatment, those being vaccinated, along with reviewing the current and long treatment outcomes associated with the novel coronavirus disease. The need for the immediate and global sharing of samples, data and expertise has been critical in highlighting the utility of infrastructures and their networks, and in eventually leading to the production of vaccines. However, a global network made up of scientists, researchers, physicians, and other stakeholders, must have a common vision and language in order to succeed. This could create for example, a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank can be centrally managed to ensure the standardized data and its quality and provide the necessary samples for research.

Data Sharing Towards a Sustainable Precision Medicine Health Care System
Rita Lawlor, ARC-Net Cancer Research Centre, University of Verona , Italy

Data Sharing In Biobanking: Difficulties and Opportunities
Karine Sargsyan, University of Graz, Austria

The Role of Virtual Biobanking Networks During the COVID-19 Pandemic
Morag McFarlane, Tissue Solutions, UK

Leveraging and Aligning in-House Resources of an Established, System-wide Virtual Biobank at Christus Health to Enhance Biospecimen Research During COVID-19 Pandemic
Pukar Ratti, CHRISTUS Institute for Innovation & Advanced Clinical Care, USA

Oral Abstract Presentations

Consenting Trends During a Pandemic: How COVID-19 has Affected Clinical Research
Avani Pendse, Duke University Health System, USA

European Biobanks in the Coronavirus Environment
Judita Kinkorova, University Hospital in Pilsen, Czechia

FIND Integrated Biobanks (FIB) and Virtual Biobank Directory (VBD): A Framework for Sample Access and Sharing to Facilitate Diagnostic Development and Evaluation and Pandemic Preparedness
Anna Mantsoki, FIND, Switzerland

Application of Natural Language Processing for Biorepositories
Patricia Castro, Baylor College of Medicine, USA

Oral Abstract Presentations

QBB Rapid Transformation into COVID-19 Biorepository: A Showcase
Eleni Fthenou, Qatar Biobank for Medical Research, Qatar

Data Management Tools in the NIST Biorepository
Jared Ragland, National Institute of Standards and Technology, USA

In Extraordinary Times: Resetting the Bar of Sustainability and Opportunity - Observability of Value for Biobanks
Daniel Simeon-Dubach, medservice, Switzerland

ISO 20387 Accreditation, Corrective Actions, and Deficiencies So Far
Cory Arant, A2LA, USA

Round Table Discussions

Biobanking during Covid: Minimizing Risk and Maximizing Operations
Facilitator: Laura Scheinfeldt, Coriell Institute for Medical Research, USA

Global Implementation of ISO 20387: Challenges and Opportunities
Facilitator: Clare Allocca, National Institute of Standards and Technology, USA

Federated Representation of Specimens Collections in Central Repository through Metadata Harmonization using Established Terminology Standards
Facilitator: Alexandra Shlionskaya, Booz Allen Hamilton, USA

Increasing Public Engagement and Diversity in Biobanking
Facilitators: Helena Ellis, Biobanking Without Borders, LLC, USA, Carol Weil, National Institute of Health, USA, Esmeralda Casas-Silva, National Cancer Institute, USA

Poster Abstract Presentations

Join us in the poster hall to peruse the latest research in biobanking and connect directly with the poster presenters. All poster presenters are available within their poster booth to videoconference with delegates.

Networking with China and the Indo-Pacific Rim

Join us for networking with fellow delegates from around the globe.

Networking with China and the Indo-Pacific Rim

Join us for networking with fellow delegates from around the globe.

Rising Stars: The Next Generation of Biobankers

This session aims to promote new stars in biobanking, including young biobanks, newbie biobank-ers, and new achievements of biobanking. Show the world your first stone and your baby steps, let them know how tough you are! This session creates a dancing zone for any early-stage aspects of biobanking. It is also a chance to show your needs, and we are all together to help.

Okadai Biobank: Biobank-as-a-Service in a University Hospital in Japan
Mizuki Morita, Okoyama University, Japan

The Current Status of Biobanking in Vietnam
Tiến Anh Ngô, Vinmec Healthcare System, Vietnam

An Indian Experience with the Progress of National Biobank
Birendra Kumar Yadav, India National Liver Disease Biobank, India

Effect of Ascorbic Acid on Metabolic Status, Lipid Peroxidation, Antioxidant Activity and Quality of Frozen Indian Red Jungle Fowl (Gallus gallus murghi) Semen
Bushra Allah Rakha, Pir Mehr Ali Shah Arid Agriculture University Rawalpindi, Pakistan

Biobank Cancer Hospital: 14 Years in Translation Cancer Research
Márcia Marques Silveira, Barretos Cancer Hospital , Brazil

What You Need to Know to Cooperate With Pharma and the Diagnostics Industry

Since human biospecimen are a critical resource to translate research from bench to bedside, collaboration between Industry and Biobanks is of paramount importance. This important collaboration is often sub-optimal, as the parties each have their own unique priorities, requirements, and regulatory constraints. During this session, we will explain the main drivers behind Industry demand for biospecimen and the perspective of academic biobanks, highlight some obstacles to collaboration, and explore potential solutions to optimize cooperation.

This session has been organized by the ISBER Pharma Working Group.

What are the main biospecimen sources used by Pharma-IVD industry?
Pascal Puchois, Trans-Hit Biomarkers, a Brooks Life Sciences Company, Canada

Collaboration between Academic Biobanks and Biotech Industry: Pitfalls and Lessons Learned
Daniel Simeon-Dubach, medservice, Switzerland

Material Transfer Agreements: How to Align Industry's and Academia's Interests
Donna Wren, Faber Daeufer & Itrato P.C., USA

Diagnostics Industry Prospective: What Drives Biospecimen Utilization in New Product Development
Kerry Powers, Ventana, USA

The Synergistic Partnership between Pharma and Academic Pathology for Companion Diagnostics
Michael Roehrl, Memorial Sloan Kettering Cancer Center, USA

An Increased Need for Building Prospective Fit for Purpose Biospecimen Collections: Impact on R&D Programs
Suresh Selvaraj, Genentech, USA

Managing Pre-Analytic Variables in a High Quality Biobank
Chris Andry, Boston Medical Center, USA